AstraZeneca reported updated Phase 3 SERENA-6 trial results showing that camizestrant combined with a CDK4/6 inhibitor significantly improved progression-free survival in hormone receptor-positive, HER2-negative advanced breast cancer. The treatment reduced the risk of disease progression or death by 55%, extending median progression-free survival to 16.8 months compared to 9.2 months with aromatase inhibitors. Benefits persisted beyond initial progression, with longer second progression-free survival and delayed need for chemotherapy. Exploratory analyses also showed substantial reductions in circulating tumor DNA, indicating strong biological activity. Overall survival data are still immature, with the trial ongoing for final analysis.
AstraZeneca's Phase 3 EMERALD-3 trial demonstrated that the STRIDE regimen, combining immunotherapy drugs Imfinzi and Imjudo with lenvatinib and TACE, significantly improved progression-free survival by 30% compared to TACE alone in patients with unr...
At ASCO 2026, European pharma firms had a quiet showing, but AstraZeneca and Roche faced key challenges. AstraZeneca's lung cancer drug Datroway competes with Merck's sac-TMT, which showed strong efficacy but high toxicity, making AstraZeneca's bioma...
Citi views the upcoming phase three trial results for AstraZeneca's heart drug Wainua as favorable, expecting positive outcomes that could significantly boost sales. Wainua targets ATTR-cardiomyopathy by suppressing transthyretin protein production, ...
CelLBxHealth PLC has signed a master services agreement with AstraZeneca, enabling it to provide circulating tumour cell (CTC) analytics for AstraZeneca's drug discovery and development. Using its Parsortix platform, CelLBxHealth will analyze CTCs fr...
